[HTML][HTML] Challenges identifying efficacious miRNA therapeutics for cancer

M Segal, FJ Slack - Expert opinion on drug discovery, 2020 - Taylor & Francis
MicroRNAs are a class of small non-coding RNAs (22-23 nucleotides), which regulate gene
expression at the posttranscriptional level and play key roles in tumorigenesis and other …

[HTML][HTML] Challenges identifying efficacious miRNA therapeutics for cancer

M Segal, FJ Slack - Expert opinion on drug discovery, 2020 - ncbi.nlm.nih.gov
MicroRNAs are a class of small non-coding RNAs (22–23 nucleotides), which regulate gene
expression at the post-transcriptional level and play key roles in tumorigenesis and other …

[引用][C] Challenges identifying efficacious miRNA therapeutics for cancer

M Segal, FJ Slack - Expert opinion on drug discovery, 2020 - pubmed.ncbi.nlm.nih.gov
Challenges identifying efficacious miRNA therapeutics for cancer Challenges identifying
efficacious miRNA therapeutics for cancer Expert Opin Drug Discov. 2020 Sep;15(9):987-992 …

Challenges identifying efficacious miRNA therapeutics for cancer.

M Segal, FJ Slack - Expert Opinion on Drug Discovery, 2020 - europepmc.org
MicroRNAs are a class of small non-coding RNAs (22–23 nucleotides), which regulate gene
expression at the post-transcriptional level and play key roles in tumorigenesis and other …

[PDF][PDF] Challenges identifying efficacious miRNA therapeutics for cancer

M Segal, FJ Slack - EXPERT OPINION ON DRUG DISCOVERY, 2020 - academia.edu
MicroRNAs are a class of small non-coding RNAs (22-23 nucleotides), which regulate gene
expression at the posttranscriptional level and play key roles in tumorigenesis and other …